Newborn Screening Market was valued at ~US$ 940 Mn in 2019 and is projected to expand at a CAGR of ~11% from 2021 to 2031, rise in prevalence and incidence of critical congenital heart defects and improved & precise diagnosis of NICU diseases to drive the market
Newborn Screening Market: Introduction
According to the report, the global newborn screening market was valued at ~US$ 940 Mn in 2019 and is
projected to expand at a CAGR of ~11% from 2021 to 2031. Newborn screening is a preventive pediatric
screening test conducted to diagnose congenital or inborn abnormalities of metabolism in order to
identify the disease. Newborn screening helps in the early detection of serious genetic diseases, which
may result in disability or death if not treated at the initial stage. Different types of instrument and assay
kits are used in the diagnosis of newborn disorders. Hearing screening devices and pulse oximeter are
regularly used in the diagnosis of newborn disorders.
The growth of the global newborn screening market can be ascribed to the rise in prevalence of critical
congenital heart defects and government support. The U.S. has a national program of newborn screening
tests to check for several different disorders that can be treated, if found very early in life.
Request Brochure of Report -
North America dominated the global newborn screening market in 2019. This trend is anticipated to
continue during the forecast period. Highly structured healthcare industry, early new product adoption,
high prevalence rate of critical congenital heart diseases, and presence of major players are expected to
drive the newborn screening market in North America. Asia Pacific is anticipated to be a highly lucrative
region of the global newborn screening market during the forecast period. The market in the region is
projected to expand at a high CAGR during the forecast period.
Rise in Prevalence of Critical Congenital Heart Defects and Government Support to Drive Global Market
Rise in prevalence and incidence of critical congenital heart diseases across the globe are driving the global
newborn screening market. According to the National Center for Biotechnology Information, about 1.35